Thomas Capozza, MD

Senior Director, Scientific Affairs
Intercept Pharmaceuticals, Inc.

Presentation(s):

• OP-7A - Impact of Non-alcoholic Steatohepatitis (NASH) Case Definition on Population Characteristics Identified in a US Claims Database

  Wednesday, August 25, 2021
  11:45 AM – 1:30 PM US Eastern Time

• OP-7F - Incidence Rates of Select Outcomes Among Patients with Non-alcoholic Steatohepatitis (NASH) and Evidence of Fibrosis and Cirrhosis

  Wednesday, August 25, 2021
  11:45 AM – 1:30 PM US Eastern Time